Skip to main content
. 2018 May 22;124(13):2801–2814. doi: 10.1002/cncr.31549

Figure 1.

Figure 1

Trends in the proportion of men aged ≥50 years who received PSA testing in the prior year in the United States in 1987‐2005 (reconstructed from data from Medicare claims and the NHIS and based on methodology in Mariotto et al12) and trends in age‐ and delay‐adjusted prostate cancer incidence rates among men of all races combined by stage at diagnosis in SEER 9 in 1975‐2014. (A) Percentage of men having at least 1 PSA test in the prior year and their first PSA test in the prior year (NHIS): ages ≥ 50 years. (B) Prostate cancer incidence rates (SEER 9): all stages and all races. (C) Prostate cancer incidence rates (SEER 9): distant stage and all races. Rates are per 100,000 persons and have been age‐adjusted to the 2000 US standard population and delay‐adjusted for age and stage at diagnosis. Note that the y‐axis ratio for panel B to panel C is 10:1. The SEER 9 registries are Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco–Oakland, Seattle–Puget Sound, and Utah. ^The trend was statistically significant from 0 (P < .05). APC indicates annual percent change; NHIS, National Health Interview Survey; PSA, prostate‐specific antigen; SEER, Surveillance, Epidemiology, and End Results.